‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

Research output: Contribution to journalDebate/Note/Editorial

Details

Authors
  • Dimitrios C. Mastellos
  • E. Sander Connolly
  • Mohamed R. Daha
  • Brian V. Geisbrecht
  • Berhane Ghebrehiwet
  • Piet Gros
  • George Hajishengallis
  • V. Michael Holers
  • Markus Huber-Lang
  • Taroh Kinoshita
  • Tom E. Mollnes
  • Robert A. Montgomery
  • B. Paul Morgan
  • Bo Nilsson
  • Ruben Pio
  • Daniel Ricklin
  • Antonio M. Risitano
  • Ronald P. Taylor
  • Alberto Mantovani
  • John P.A. Ioannidis
  • John D. Lambris
Organisations
External organisations
  • National Centre for Scientific Research Demokritos
  • Columbia University
  • Leiden University Medical Centre
  • Kansas State University
  • Stony Brook University
  • Utrecht University
  • University of Pennsylvania
  • University of Ulm
  • Osaka University
  • Oslo university hospital
  • Nordland Hospital Bodø
  • Norwegian University of Science and Technology
  • New York University
  • Cardiff University
  • Uppsala University Hospital
  • CIBERONC Centro de Investigación Biomédica en Red Cáncer
  • University of Basel
  • University of Naples Federico II
  • University of Virginia
  • Humanitas Research Hospital
  • Stanford University
  • University of Colorado
  • University of Oslo
  • University of Navarra
  • Humanitas University
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Pharmaceutical Sciences
  • Health Care Service and Management, Health Policy and Services and Health Economy
Original languageEnglish
Pages (from-to)1409-1413
Number of pages5
JournalNature Immunology
Volume20
Issue number11
Publication statusPublished - 2019
Publication categoryResearch
Peer-reviewedYes